White matter integrity and cognition in Parkinson's disease: a cross-sectional study

Objective We used diffusion tensor imaging (DTI) to test the following hypotheses: (1) there is decreased white matter (WM) integrity in non-demented Parkinson’s disease (PD), (2) WM integrity is differentially reduced in PD and early Alzheimer’s disease (AD) and (3) DTI changes in non-demented PD are specifically associated with cognitive performance. Methods This study included 18 non-demented patients with PD, 18 patients with mild cognitive impairment due to incipient AD and 19 healthy elderly normal control (NC) participants in a cross-sectional design. The participants underwent DTI, and tract-based spatial statistics was used to analyse and extract radial diffusivity and fractional anisotropy. Correlations between scores from a battery of neuropsychological tests and DTI were performed in the PD group. Results Patients with PD had significant differences in DTI in WM underlying the temporal, parietal and occipital cortex as compared with NC. There were no significant differences between the PD and AD groups in the primary region of interest analyses, but compared with NC there was a tendency for more anterior changes in AD in contrast to more posterior changes in PD. In a secondary whole-brain analysis there were frontoparietal areas with significant differences between AD and PD. In patients with PD, there were significant correlations between DTI parameters in WM underlying the prefrontal cortex and executive and visuospatial abilities. Conclusions In early, non-demented PD we found reduced WM integrity underlying the temporal, parietal and occipital cortices. In addition, WM integrity changes in prefrontal areas were associated with executive and visuospatial ability. These findings support that DTI may be an important biomarker in early PD, and that WM changes are related to cognitive impairment in PD.

[1]  Massimo Filippi,et al.  Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage , 2014, Human brain mapping.

[2]  T. Anderson,et al.  White matter microstructure deteriorates across cognitive stages in Parkinson disease , 2013, Neurology.

[3]  O. Abe,et al.  Relationship between cognitive impairment and white-matter alteration in Parkinson’s disease with dementia: tract-based spatial statistics and tract-specific analysis , 2013, European Radiology.

[4]  P. Selnes,et al.  Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. , 2013, Journal of Alzheimer's disease : JAD.

[5]  B. Myors,et al.  Australian Norms and Retest Data for the Rey Auditory and Verbal Learning Test , 2012 .

[6]  Jiabao He,et al.  Characterizing dementia with Lewy bodies by means of diffusion tensor imaging , 2012, Neurology.

[7]  P. Svenningsson,et al.  Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment , 2012, The Lancet Neurology.

[8]  O. Abe,et al.  White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract–Specific Analysis , 2012, American Journal of Neuroradiology.

[9]  O. Abe,et al.  Cognitive status correlates with white matter alteration in Parkinson's disease , 2012, Human brain mapping.

[10]  Wang Zhan,et al.  Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging , 2012, Movement disorders : official journal of the Movement Disorder Society.

[11]  Nicolaas I. Bohnen,et al.  White matter lesions in Parkinson disease , 2011, Nature Reviews Neurology.

[12]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[13]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[14]  J. Leverenz,et al.  Profile of Cognitive Impairment in Parkinson's Disease , 2010, Brain pathology.

[15]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Mark W. Woolrich,et al.  Bayesian analysis of neuroimaging data in FSL , 2009, NeuroImage.

[17]  K. Walhovd,et al.  Morphometric Changes in the Episodic Memory Network and Tau Pathologic Features Correlate with Memory Performance in Patients with Mild Cognitive Impairment , 2008, American Journal of Neuroradiology.

[18]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[19]  R. Dean,et al.  TEST REVIEW: Dean C. Delis, Edith Kaplan & Joel H. Kramer, Delis Kaplan Executive Function System (D-KEFS), The Psychological Corporation, San Antonio, TX, 2001. $415.00 (complete kit) , 2006 .

[20]  Daniel Rueckert,et al.  Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data , 2006, NeuroImage.

[21]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[22]  J. Alvarez,et al.  Executive Function and the Frontal Lobes: A Meta-Analytic Review , 2006, Neuropsychology Review.

[23]  G. Stebbins,et al.  Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model , 2005, Movement disorders : official journal of the Movement Disorder Society.

[24]  U P Mosimann,et al.  Visual perception in Parkinson disease dementia and dementia with Lewy bodies , 2004, Neurology.

[25]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.

[26]  Takashi Kato,et al.  Occipital hypoperfusion in Parkinson’s disease without dementia: correlation to impaired cortical visual processing , 2003, Journal of neurology, neurosurgery, and psychiatry.

[27]  John T. O'Brien,et al.  A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[29]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[30]  O. Almeida,et al.  Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD‐10 and DSM‐IV , 1999, International journal of geriatric psychiatry.

[31]  Daniel Rueckert,et al.  Nonrigid registration using free-form deformations: application to breast MR images , 1999, IEEE Transactions on Medical Imaging.

[32]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[33]  J. Cummings,et al.  Frontal-subcortical circuits and human behavior. , 1993, Journal of psychosomatic research.

[34]  B. Reisberg,et al.  The GDS/FAST Staging System , 1997, International Psychogeriatrics.

[35]  Leslie G. Ungerleider,et al.  ‘What’ and ‘where’ in the human brain , 1994, Current Opinion in Neurobiology.

[36]  W. Weiner,et al.  Visuospatial impairment in Parkinson's disease , 1991, Neurology.

[37]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.

[38]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[39]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[40]  F. Boller,et al.  Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. , 1984, Archives of neurology.

[41]  M. Kuskowski,et al.  Dementia in Parkinson disease: A neuropsychological analysis , 1982, Brain and Cognition.